Armed Forces Institute of Regenerative Medicine - II (AFIRM II)

The summary for the Armed Forces Institute of Regenerative Medicine - II (AFIRM II) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

Armed Forces Institute of Regenerative Medicine - II (AFIRM II): The Armed Forces Institute of Regenerative Medicine (AFIRM) is dedicated to repairing battlefield injuries through the use of regenerative medicine technologies and associated sciences. Therapies developed by the AFIRM II program are intended to aid traumatically injured Wounded Warriors as well as to benefit those within the civilian sector. One of the goals of the program is to position promising technologies and therapeutic/restorative practices for entrance into human clinical trials. The intent of the AFIRM II program is to fund basic through translational regenerative medicine research and development. Activities acceptable under this award may include basic scientific research, development of animal models, preclinical studies required for initiation of FDA-regulated human clinical trials, and Phase I - II human clinical trials. Therefore, it is not the intent to fund human clinical trials as a major component of this program. It is envisioned that integration of basic science, translational and clinical research efforts will be necessary to advance effective regenerative medicine treatments for combat-related injuries. The Offeror's organization should actively seek out and establish partnerships with industry to ensure that the technical innovations emerging from the research will transition into clinical applications and result in FDA approved treatments. Offerors are encouraged to seek collaboration with Government laboratories and Medical Centers/Medical Treatment Facilities such as those in the Army, Navy, Air Force, NIH and VA, if mutually beneficial.